HP Appoints Emma Walmsley as New CEO

The news headline pertains to HP and does not directly affect MSFT's fundamentals; thus, its impact on MSFT should be limited and indirect. Technical indicators point to strong short-term momentum: price has increased 6.26% in 24 hours, RSI14 at 73.8 is in overbought territory, and MACD is above its signal line. However, due to the overbought condition and the news's irrelevance, further upward movement is likely to be limited, and profit-taking may even occur. Therefore, the 1-3 day outlook is neutral; directional uncertainty is high.

HP's appointment of Emma Walmsley as its new CEO may be perceived as mildly positive in the short term, as it reduces uncertainty regarding management changes. The stock has risen 4.8% over the past 24 hours and its RSI stands at 60, not yet entering overbought territory. The price is trading above the SMA20 but below the SMA50; although the MACD remains in negative territory, it is above the signal line, indicating a weak recovery signal. As the new CEO's strategic impact is not yet clear, the reaction may remain limited; therefore, I view the direction as upward but cautious.

GSK shares rose 3.4% in the last 24 hours to reach 51.24, with RSI14 at 76 placing it in overbought territory. MACD is above the signal line and the price is above SMA20/SMA50, indicating strong short-term momentum. However, the news headline is unrelated to GSK, reporting HP's CEO appointment; therefore, no direct impact on GSK should be expected. Given the overbought level and the unrelated news, a sideways or slight correction trend is likely in the short term. Nevertheless, the current technical picture alone does not entirely eliminate upside risk.